drugset / Trial / NCT00324376

Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

NCT00324376

Phase 2 Completed 24 enrolled Genzyme, a Sanofi Company
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, cross-over, open-label study will be conducted to evaluate the equivalency, safety and tolerability of sevelamer once per day dosing, given with the largest meal, compared with standard three times per day dosing, in hemodialysis patients previously using sevelamer. Following a two week Run-In period, a total of 24 patients will be randomized to one of the following treatment sequences: 1. sevelamer dosed once a day with the largest meal followed by standard three times per day dosing with meals 2. sevelamer dosed three times per day with meals followed by once a day dosing with the largest meal. Patients will maintain a fixed daily dose throughout both treatment periods based on the most recently prescribed sevelamer dose prior to screening.

Timeline

Start
2003-03
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevelamer Other / unclassified